Phase 3 Readout

KURA: Phase 3 Topline: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination Wit

Name: Phase 3 Topline: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination Wit
Start: 2031-11-01
End: 2031-11-01

November 1, 2031. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: November 1, 2031
Company: Kura Oncology, Inc. (KURA)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination Wit

November 1, 2031

KURA overview →

Company: Kura Oncology, Inc. (KURA)
Indication: Acute Myeloid Leukemia (AML)